Gyre Therapeutics, Inc. (Nasdaq: GYRE), an SEC filer in Pharmaceutical Preparations, closed at $6.59, -1.3%, on 2026-08-28, with a market cap of $735M, a trailing P/E of 329.5, a return on equity of 11.7%, a net margin of 8.5% and 3-year sales growth of 4.5%. Institutional ownership, earnings history and filed financials are on the tabs below.
| Market Cap | $734.8M | |
| Enterprise Value | — | |
| Revenue | $116.4M | +10.2% |
| Gross Profit | $102.4M | +9.1% |
| EBITDA | -$9.2M | −21.1% |
| Net Income | -$25.7M | −44.8% |
| Diluted EPS | $0.02 | −60.0% |
| Free Cash Flow | -$6.1M | — |
Bars are the value as filed for every stored fiscal year (oldest → newest, the latest bar solid); a year the store has no value for is left EMPTY. Free cash flow is operating cash flow less capital expenditures for the same year — the only figure here computed from two lines, and a year missing either one is a gap. The 3y/5y/10y CAGRs are the analytics core’s own (positive-base only); no rate is recomputed on this strip, and no rate is shown for a series the core doesn’t publish one for. Diluted EPS is drawn on ONE share basis: as-filed per-share figures from before a split are stated on the old basis, so where the implied share count breaks (net income ÷ EPS, ±1.45× band — the same acceptance band the API’s own classifier uses) the earlier bars are left undrawn and any CAGR horizon reaching past the break is suppressed rather than shown as a rate across two different bases.
Every bar is a figure as filed. Anything a filed line doesn’t explain is drawn as a residual, never absorbed into a neighbouring step.
This filer skips: gross profit.
Reconciliation.
| Step | Applied | Running level | % of revenue | 2024 |
|---|---|---|---|---|
| Revenue · reported | $116.6M | $116.6M | 100.0% | $105.8M |
| Cost of revenue | -$5.4M | $111.2M | −4.6% | $3.9M |
| R&D | -$13.7M | $97.5M | −11.7% | $12.0M |
| Selling & marketing | -$65.2M | $32.3M | −55.9% | $57.5M |
| SG&A | -$20.8M | $11.5M | −17.8% | $16.1M |
| Other (residual) · residual | -$4,000 | $11.5M | −0.0% | — |
| Operating income · reported | $11.5M | $11.5M | 9.9% | $16.2M |
| Other non-operating | -$1.5M | $10.0M | −1.3% | $1.7M |
| Other (residual) · residual | $4.5M | $14.4M | 3.8% | — |
| Pretax income · reported | $14.4M | $14.4M | 12.4% | $23.2M |
| Income tax | -$4.6M | $9.9M | −3.9% | $5.3M |
| Minority interest | -$4.9M | $5.0M | −4.2% | $5.8M |
| Other (residual) · residual | $4.9M | $9.9M | 4.2% | — |
| Net income · reported | $9.9M | $9.9M | 8.5% | $17.9M |
Cumulative operating cash flow over FY2020–FY2025 is -$104.9M — not positive, so there is no operating-cash pool to allocate and no bridge is drawn. Lenders and other balance-sheet businesses routinely report negative operating cash flow (loan originations run through it); read the cash-flow statement directly below.
| DPS (FY2022) | $0.24 |
| Trailing yield | 3.64% |
| Payout ratio | 1043.8% |
| Growth streak | 0 yrs |
| 5y DPS growth | — |
| Fiscal year | DPS | YoY | Basis |
|---|---|---|---|
| FY20222022-12-31 | $0.24 | — | reported |
| Ex-date | Amount | Pay date | Freq | Source |
|---|---|---|---|---|
| 2023-01-13 | $0.2400 | 2023-01-12 | quarterly | licensed |
| 2022-09-21 | $1.43 | 2022-09-20 | quarterly | licensed |
| 2022-09-02 | $1.43 | — | quarterly | licensed |
| 2015-08-20 | $0.5700 | — | quarterly | licensed |
None of the three composites is computable for this filer — each needs two consecutive fiscal years of specific lines (COGS, PP&E, receivables), which many financials and asset-light names legitimately never tag. The trend below is what the store does serve.
| Quality trend | 2025 | Δ vs 2020 | Trend · 6y | vs own | vs sector |
|---|---|---|---|---|---|
| Gross Margin | 95.4% | — | p38 | p98 | |
| Operating Margin | 9.9% | +283.7pp | p75 | p72 | |
| Net Margin | 8.5% | +277.0pp | p75 | p75 | |
| Return on Equity | 11.7% | — | p83 | p75 |
Three scores, kept separate. They are not averaged into one “quality” number. They point in different directions (F is a 0–9 count, higher-better; Z is a distress distance, higher-safer; M is a manipulation screen, lower-cleaner) and were fitted on different samples for different questions — a blended figure would be ours, not theirs, and would hide exactly the disagreement that is worth reading.
Sector context. The percentile columns on the trend rows are the ones this payload serves: “vs own” ranks the latest value inside this company’s own served history, “vs sector” inside its sector pool. A blank sector cell means the pool was too thin to rank honestly (or the metric is a currency level, where a cross-currency rank would be meaningless). The three SCORES carry no sector percentile: the payload’s percentile block covers the served ratios only, so “is this Z good for Manufacturing?” is a question we cannot answer from what is served, and we don’t pretend to.
Latest vintage only. A 12-year F-Score / Z-Score strip is not drawn. The point-in-time factor store carries valuation, returns, margin, momentum and growth factors — not these composites — and recomputing them here from the annual columns would produce a series that disagrees with the headline above (different vintage of facts, different restatement handling). A score that disagrees with itself is a wrong number, so the history is omitted rather than approximated.
The nine named F-Score checks, the Merton distance-to-default / default probability, ROIIC and the growth-durability CAGRs live on FS · Financial Strength; the full ratio grid — every served ratio, with its own trend and both percentiles — is the Ratios section below.
Drivers multiply to 10.6% vs reported ROE 11.7%.
| Line | 2020↗ | 2021↗ | 2022↗ | 2023↗ | 2024↗ | 2025↗ |
|---|---|---|---|---|---|---|
| Revenue | $20.9M | $7.3M | $102.3M | $113.5M | $105.8M | $116.6M |
| YoY % | -65.0% | +1294.0% | +10.9% | -6.8% | +10.2% | |
| Cost of Revenue | — | — | $4.8M | $4.6M | $3.9M | $5.4M |
| YoY % | -3.3% | -16.2% | +39.4% | |||
| Gross Profit | — | — | $97.5M | $108.8M | $101.9M | — |
| YoY % | +11.6% | -6.4% | ||||
| R&D Expense | $53.0M | $68.9M | — | $13.8M | $12.0M | $13.7M |
| YoY % | +30.0% | -12.7% | +13.9% | |||
| Selling & Marketing Expense | — | — | $54.2M | $61.2M | $57.5M | $65.2M |
| YoY % | +12.8% | -6.0% | +13.3% | |||
| SG&A Expense | $16.2M | $19.0M | $17.4M | $14.7M | $16.1M | $20.8M |
| YoY % | +17.2% | -8.4% | -15.6% | +9.9% | +29.1% | |
| Total Operating Expenses | $78.3M | $95.2M | $88.3M | $176.0M | $89.6M | $105.1M |
| YoY % | +21.6% | -7.3% | +99.4% | -49.1% | +17.3% | |
| Operating Income | -$57.4M | -$87.9M | $9.2M | -$67.2M | $16.2M | $11.5M |
| YoY % | -28.9% | |||||
| Other Non-Operating Income | -$91,000 | -$78,000 | — | -$1.5M | -$1.7M | -$1.5M |
| Impairment of Real Estate | — | — | $0 | $0 | $0 | $0 |
| Pretax Income | — | -$87.9M | $9.4M | -$77.0M | $23.2M | $14.4M |
| YoY % | -37.8% | |||||
| Income Tax | — | — | $5.1M | $8.5M | $5.3M | $4.6M |
| YoY % | +67.0% | -37.5% | -14.4% | |||
| Net Income (incl. NCI) | -$56.2M | -$87.9M | $4.3M | -$85.5M | $17.9M | $9.9M |
| YoY % | -44.8% | |||||
| Minority Interest (P&L) | — | — | $2.0M | $7.5M | $5.8M | $4.9M |
| YoY % | +270.4% | -22.0% | -16.5% | |||
| Net Income | -$56.2M | -$87.9M | $4.3M | -$85.5M | $17.9M | $9.9M |
| YoY % | -44.8% | |||||
| Net Income to Common | -$56.2M | — | $2.3M | -$92.9M | $12.1M | $5.0M |
| YoY % | -58.4% | |||||
| EPS (Basic) | — | -$2.87 | $0.04 | -$1.41 | $0.14 | $0.06 |
| YoY % | -57.1% | |||||
| EPS (Diluted) | — | -$2.87 | $0.03 | -$1.41 | $0.05 | $0.02 |
| YoY % | -60.0% | |||||
| Weighted Avg Shares (Basic) | — | 30.6M | 63.6M | 65.8M | 85.1M | 89.3M |
| YoY % | +107.5% | +3.5% | +29.3% | +5.0% | ||
| Weighted Avg Shares (Diluted) | — | 30.6M | 75.7M | 65.8M | 102.3M | 103.2M |
| YoY % | +147.0% | -13.0% | +55.4% | +0.9% | ||
| Dividends Declared per Share | — | — | $0 | — | — | — |
Sector is SIC-based, not GICS. A blank cell means the figure wasn't filed.
